CDER Division of Drug Labeling Compliance
Deputy Director Mary Richardson begins 60-day detail as Division of Scientific Investigations deputy director Feb. 20. Former scientific investigations deputy director Ross Laderman has left FDA for Guilford Pharmaceuticals ("The Pink Sheet" Feb. 7, In Brief). Prescription Drug Compliance Branch Chief Frank Fazzari is acting director of the labeling compliance division until Richardson returns April 30. The division's director Richard Chastonay retired March 1
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth